

### REMARKS

Claims 21-34 are now pending for the Examiner's review and consideration. This application is a continuation of application no. 09/985,099, filed November 1, 2001, now allowed; which is a continuation of Application No. 09/515,407, filed February 29, 2000, now U.S. patent no. 6,548,082, which claims the benefit of U.S. provisional application no. 60/122,274, filed March 1, 1999. New claims 21-34 recite compositions comprising a therapeutically effective amount of R(+) ondansetron, or a pharmaceutically acceptable salt thereof, substantially free of its S(-) stereoisomer, and a therapeutically effective amount of at least one other therapeutic agent (*See, e.g.,* Specification, page 4, line 26 to page 5, line 8). No new matter has been added. Entry of the foregoing amendments prior to examination is respectfully requested. An early allowance is earnestly sought.

No fee is believed to be due for this submission. Should any fees be required, however, please charge the required fees to Pennie & Edmonds LLP Deposit Account No. 16-1150.

Respectfully submitted,

Date: September 22, 2003



Paul E. Dietze (Reg. No. 45,627)

For: Anthony M. Insogna (Reg. No. 35,203)

**PENNIE & EDMONDS LLP**

1667 K Street, N.W.

Washington, DC 20006

(202) 496-4400